Equity Overview
Price & Market Data
Price: $0.933
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $1,175,947,776
Volume: 0
Performance Metrics
1 Week: 4.41%
1 Month: 14.50%
3 Months: 2.66%
6 Months: 344.0%
1 Year: 455.7%
YTD: 42.89%
Company Details
Employees: 231
Sector: Health technology
Industry: Biotechnology
Country: China
Details
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.